[go: up one dir, main page]

BRPI0508970A - método combinatórios e composições para o tratamento de melanoma - Google Patents

método combinatórios e composições para o tratamento de melanoma

Info

Publication number
BRPI0508970A
BRPI0508970A BRPI0508970-0A BRPI0508970A BRPI0508970A BR PI0508970 A BRPI0508970 A BR PI0508970A BR PI0508970 A BRPI0508970 A BR PI0508970A BR PI0508970 A BRPI0508970 A BR PI0508970A
Authority
BR
Brazil
Prior art keywords
melanoma
agent
melanoma tumor
tumor
mammal
Prior art date
Application number
BRPI0508970-0A
Other languages
English (en)
Inventor
Gavin P Robertson
Mark Kester
Lakshman Sandirasegarane
Arati Sharma
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of BRPI0508970A publication Critical patent/BRPI0508970A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MéTODOS COMBINATóRIOS E COMPOSIçõES PARA O TRATAMENTO DE MELANOMA A presente invenção propõe uma base racional para se combinar terapia dercionada juntamente com quimioterápicos selecionados que não existe ataulmente para o tratamento de melanoma. A presente invenção é baseada na descoberta dos inventores da presente invenção de que AKt3 regula a apoptose e que V599E B-Raf regula o crescimento e o desenvolvimento vascular em melanoma. Os inventores são os primeiros a reconhecer uma terapia direcionada combinada efetiva para o tratamento de melanoma. Em uma modalidade,a invenção propõe um método para a indução de apoptose em uma célula tumoral de melanoma por redução da atividade de AKt3. Em outra modalidade, a invenção um método para a indução de apoptose em uma célula tumoral de melanoma que compreende colacar-se uma célula melanoma em contato com um agente que reduz a atividade de AKt3.Consequentemente, o método proposto restaura uma sensibilidade apoptótica normal a uma célula tumoral de melanoma, permitindo assim a administração de uma concentração mais baixa de agentes quimioterápicos resultando em uma toxicidade reduzida um paciente. Os inventores da presente invenção comtemplam um método para o tratamento de um tumor de melnoma em um mamífero que compreende: a administração a um tumor de melanoma de uma quantidade efetiva de um agente para induzir apoptose; e administração a um tumo de melanoma de uma quantidade efetiva de um agente para reduzir a angiogênese e a proliferação celular. Também é descrito na presente invenção um método para tratamento de um melanoma em um mamífero, que compreende : a administração, a um tumor de melanoma em um mamífero,de uma quantidade efetiva de um agente que reduz atividade de AKt3, a administração, a um tumor de melanoma em um mamífero,de uma quantidade efetiva de um agente que reduz a atividade de V599E B-Raf, tratando assim um tumor de melanoma. Em um outro aspecto, a invenção propõe uma composição fermacêutica para o tratamento de um tumor de melanoma que compreende: um agente que reduz a atividade de AKt3; e um veículo.
BRPI0508970-0A 2004-03-19 2005-03-18 método combinatórios e composições para o tratamento de melanoma BRPI0508970A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55450904P 2004-03-19 2004-03-19
PCT/US2005/008950 WO2005089443A2 (en) 2004-03-19 2005-03-18 Combinatorial methods and compositions for treatment of melanoma

Publications (1)

Publication Number Publication Date
BRPI0508970A true BRPI0508970A (pt) 2007-08-21

Family

ID=34994352

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508970-0A BRPI0508970A (pt) 2004-03-19 2005-03-18 método combinatórios e composições para o tratamento de melanoma

Country Status (9)

Country Link
US (4) US20050267060A1 (pt)
EP (1) EP1744788A4 (pt)
JP (1) JP2007530453A (pt)
CN (1) CN101389345A (pt)
AU (1) AU2005223649A1 (pt)
BR (1) BRPI0508970A (pt)
CA (1) CA2560269A1 (pt)
MX (1) MXPA06010667A (pt)
WO (1) WO2005089443A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CN101389335A (zh) 2004-10-18 2009-03-18 安姆根有限公司 噻二唑化合物和使用方法
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2009515553A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー 癌の予知および予後と、癌治療のモニタリング
WO2008128189A1 (en) 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
US20090170925A1 (en) * 2007-10-29 2009-07-02 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010091354A2 (en) * 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
JP5641232B2 (ja) * 2010-11-24 2014-12-17 石川県公立大学法人 オゴノリ由来のシクロオキシゲナーゼの遺伝子及び該遺伝子を利用するプロスタグランジン類生産方法
CA2848173C (en) 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
CN110088136A (zh) * 2016-10-13 2019-08-02 达纳-法伯癌症研究所有限公司 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法
EP3703653A4 (en) 2017-11-03 2021-09-08 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS
CN110476953B (zh) * 2019-09-09 2021-11-12 广州中鑫基因医学科技有限公司 一种细胞活性保存液以及疾病检测试剂盒
MX2022014020A (es) * 2020-05-08 2023-02-16 Georgiamune Llc Moduladores de akt3.
CN111759794B (zh) * 2020-07-14 2023-07-21 中山大学 一种治疗黑色素瘤的微针及其制备方法
CN117110467B (zh) * 2023-08-16 2024-08-20 苏州方昆医药科技有限公司 一种醇或酚类化合物的柱前化学衍生化方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
DE60004685T2 (de) * 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US6809194B1 (en) * 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
EP1379250A2 (en) * 2001-04-10 2004-01-14 Merck & Co., Inc. A method of treating cancer
US20040136949A1 (en) * 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
US7307071B2 (en) * 2001-12-04 2007-12-11 Onyx Pharmaceuticals, Inc RAF-MEK-ERK pathway inhibitors to treat cancer
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003234336A1 (en) * 2002-05-03 2003-11-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
WO2004018676A2 (en) * 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
KR101052289B1 (ko) * 2002-08-21 2011-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 클러스테린 양의 감소에 의한 흑색종의 치료
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US20080161547A1 (en) * 2002-11-14 2008-07-03 Dharmacon, Inc. siRNA targeting serine/threonine protein kinase AKT
US20050221354A1 (en) * 2004-02-18 2005-10-06 Wyeth Nucleic acid arrays for monitoring expression profiles of drug target genes

Also Published As

Publication number Publication date
JP2007530453A (ja) 2007-11-01
EP1744788A2 (en) 2007-01-24
WO2005089443A3 (en) 2009-04-23
US20140348901A1 (en) 2014-11-27
CN101389345A (zh) 2009-03-18
EP1744788A4 (en) 2010-08-18
CA2560269A1 (en) 2005-09-29
US20130209546A1 (en) 2013-08-15
US20050267060A1 (en) 2005-12-01
WO2005089443A2 (en) 2005-09-29
US20130217949A1 (en) 2013-08-22
AU2005223649A1 (en) 2005-09-29
MXPA06010667A (es) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0508970A (pt) método combinatórios e composições para o tratamento de melanoma
Becker et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
Sountoulides et al. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management
Lin et al. Inhibition of mitochondria-and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells
Wang et al. Salvianolic acid B induces apoptosis in human glioma U87 cells through p38-mediated ROS generation
Acharya Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management
Obi et al. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
Lu et al. New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
Barone et al. A phase II study of sunitinib in advanced hepatocellular carcinoma
Yin et al. Diallyl disulfide inhibits the metastasis of type II esophageal-gastric junction adenocarcinoma cells via NF-κB and PI3K/AKT signaling pathways in vitro
Jiang et al. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
Wilson et al. Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
Wu et al. Dihydrocapsaicin (DHC) enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat
Jordan et al. Minimally invasive treatment of P eyronie's disease: evidence‐based progress
Lee et al. A telomerase-derived peptide regulates reactive oxygen species and hepatitis C virus RNA replication in HCV-infected cells via heat shock protein 90
Tang et al. Neuroprotective role of an N-acetyl serotonin derivative via activation of tropomyosin-related kinase receptor B after subarachnoid hemorrhage in a rat model
Li et al. Hydrogen sulfide decreases blood-brain barrier damage via regulating protein kinase C and tight junction after cardiac arrest in rats
BR112015009504A2 (pt) inibidores de rock
Ewend et al. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma
Landoni et al. Remote ischemic preconditioning and cardiac surgery
García et al. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients
NZ591408A (en) Paracetamol and Calcium carbonate composition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.